Clinical Trial
. 1993 Sep-Oct;64(5):533-7.
[Article in Italian]
Affiliations
- PMID: 8010582
Clinical Trial
[Rationale for the use of bile salts after cholecystectomy: results of a controlled clinical study using tauroursodeoxycholic acid (TUDCA)]
[Article in Italian]
E Croce et al. Ann Ital Chir. 1993 Sep-Oct.
Abstract
Cholecystectomy causes alterations in bile composition. In particular it rises the proportion of highly detergent bile acids with the possible consequence of the manifestation of dyspepsia in a high percentage of patients: this is the well-known post-cholecystectomy syndrome. In this clinical trial we studied the activity and safety of tauroursodeoxycholic acid--TUDCA--(500 mg/die) in the prevention of dyspepsia in cholecystectomized patients, in comparison with no treated group. We enrolled 203 patients (101 TUDCA--group A--and 102 control-group B). The two groups were comparable for age (47.1 years in group A and 50.7 years in group B), sex (m/f: 28/73 and 37/65 in the two groups) and for other characteristics connected to surgical procedures. After operation all patients suffered from dyspepsia symptoms. In patients treated with TUDCA we registered a prompt regression in severity of symptoms when compared with no treated group: in fact we noted a significant difference only at the first control planned after one month from operation. No difference were registered at the other controls (two and three months after operation). Two patients in A and 3 in group B manifested adverse events. In conclusion, the treatment with TUDCA, a new hydrophilic bile acid, seems to contribute to the improvement of clinical course in cholecystectomized patients.
Similar articles
One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.
Angelico M, Tisone G, Baiocchi L, Palmieri G, Pisani F, Negrini S, Anselmo A, Vennarecci G, Casciani CU. Angelico M, et al. Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):462-8. Ital J Gastroenterol Hepatol. 1999. PMID: 10575563 Clinical Trial.
Effect of tauroursodeoxycholic acid (TUDCA) on biliary lipid composition.
Muraca M, Vilei MT, Cianci V, Liu XT. Muraca M, et al. Ital J Gastroenterol. 1995 Oct-Nov;27(8):439-40. Ital J Gastroenterol. 1995. PMID: 8775471
Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?
Panella C, Ierardi E, De Marco MF, Barone M, Guglielmi FW, Polimeno L, Francavilla A. Panella C, et al. Ital J Gastroenterol. 1995 Jun;27(5):256-8. Ital J Gastroenterol. 1995. PMID: 8541578
Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats.
Colak A, Kelten B, Sağmanligil A, Akdemir O, Karaoğlan A, Sahan E, Celik O, Barut S. Colak A, et al. J Clin Neurosci. 2008 Jun;15(6):665-71. doi: 10.1016/j.jocn.2007.06.002. Epub 2008 Mar 14. J Clin Neurosci. 2008. PMID: 18343118
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
- MedlinePlus Health Information
Q. I have read that people who have had their gallbladders removed should take bile salts. My gallbladder was removed many years ago, and no doctor has said I should take bile salts. Should I?
A. Bile salts are produced in the liver, secreted into the bile ducts and gallbladder, and sent from there to the small intestine by way of the common bile duct. In the intestine, bile salts make it easier for your body to absorb and digest the fats and fat-soluble vitamins that you've eaten. Remember, not all fats are bad: there are "good" fats, and they are crucial to our health.
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.